Department of Cardiac, Thoracic and Vascular Science, University of Padova, Via Giustiniani 2, 35128, Padova, Italy.
Department of cardiovascular Medicine, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan.
Curr Cardiol Rep. 2021 Jan 25;23(3):15. doi: 10.1007/s11886-021-01447-w.
In this review, we discuss about the reasons behind the failure of the Absorb bioresorbable vascular scaffold (BVS) device and about the challenges the future holds for the next generation of the bioresorbable scaffold (BRS) technology.
Absorb BVS was burdened by intrinsic structural limitations which resulted in augmented rates of device thrombosis and clinical adverse events compared to current-generation metallic stent. Nevertheless, new generation devices with novel design and materials are in development. Second generation BRS have enhanced mechanical strength, smaller footprints, less thrombogenicity and modified bioresorption. These features, paired with proper patient and lesion selection and optimal "user-friendly" implant techniques, could possibly overcome the previous BRS generation limitations, rekindling physicians, and industry interest on this promising technology.
在本次综述中，我们讨论了 Absorb 生物可吸收血管支架（BVS）装置失败的原因，以及下一代生物可吸收支架（BRS）技术所面临的挑战。
Absorb BVS 存在固有结构限制，与目前的金属支架相比，导致设备血栓形成和临床不良事件的发生率增加。然而，具有新型设计和材料的新一代设备正在研发中。第二代 BRS 具有增强的机械强度、更小的占位面积、更低的血栓形成率和改良的生物可吸收性。这些特性，再加上适当的患者和病变选择以及最佳的“用户友好”植入技术，可能克服之前 BRS 代的局限性，重新激发医生和行业对这项有前途的技术的兴趣。
